Earnings 13 Apr 2026: SpineGuard SA (ALSGD.PA, EURONEXT) cash flow in focus

ALSGD.PA stock faces an earnings test on 13 April 2026, when SpineGuard SA will release results that can move intraday trading. The company trades on EURONEXT at €0.11 (current €0.1128), market cap €7.46M, and shows a one-day decline of -4.24%. Investors will watch revenue trends, cash flow and any changes to commercial guidance. With average daily volume near 686,351 and a wide year range from €0.08 to €0.30, the report could widen volatility and set short-term price direction

Earnings timing and what the ALSGD.PA stock report must show

SpineGuard’s earnings are scheduled for 13 Apr 2026. The company will be judged on top-line growth and whether operating losses narrow from recent quarters. One clear metric to watch is free cash flow per share and any changes to working capital. Management remarks on product adoption of DSG smart screw and sales in key geographies will matter for intraday volume and guidance updates.

Recent financials and valuation for ALSGD.PA stock

Trailing metrics show SpineGuard with EPS -0.04 and a negative PE. Key ratios include P/S 1.73, P/B 1.52, and current ratio 1.07. Gross margin is strong at 77.46%, but operating margin is negative at -59.40%, reflecting R&D and SG&A. The balance sheet lists cash per share €0.01 and debt-to-equity 0.54, which implies leverage but not excess risk relative to small-cap peers.

Meyka AI stock grade and technical signals for ALSGD.PA stock

Meyka AI rates ALSGD.PA with a score out of 100. Meyka AI rates ALSGD.PA with a score of 58 out of 100 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 comparison, sector and industry metrics, growth, key ratios and analyst inputs. Technical indicators show RSI 52.58, 50-day average €0.12 and 200-day average €0.11, implying neutral momentum. Short-term support is near €0.11 and resistance near €0.13.

Catalysts, risks and sector context for ALSGD.PA stock

Catalysts: positive adoption of DSG smart screw, lower operating losses, and clearer European reimbursement trends. Risks: continued cash burn, long DSO of 83 days, and low liquidity. Compared with Healthcare peers (avg P/E 29.39, avg P/B 2.53), SpineGuard trades at a valuation discount but has weaker profitability and higher operational risk.

Trading signals and practical price targets for ALSGD.PA stock

Given current dynamics, analysts and technicals imply a short-term base case target of €0.14 (≈ 24.1% upside) and a bear-case target of €0.07 (≈ -38.0% downside). Volume spikes above 686,351 average would validate directional conviction. Use tight risk limits on intraday moves, and expect swings to follow any guidance shift on 13 April.

Final Thoughts

Key takeaways for ALSGD.PA stock: the 13 April 2026 earnings release is the main near-term driver. SpineGuard trades at €0.1128 with thin market cap €7.46M and negative EPS, so the report must show improving cash flow or clearer commercial traction to restore investor confidence. Meyka AI’s forecast model projects a conservative yearly figure of €0.015113 which implies significant downside versus the current price (≈ -86.6%); this is a model-based projection and not a guarantee. For active traders the event offers intraday volatility; for longer-term holders the trade-off is proven product adoption versus continuing losses. We link to company commentary and market context and recommend watching guidance, cash flow, and revenue mix closely before adjusting positions. For quick reference see the company site and recent market coverage on Investing.com for the latest updates Meyka ALSGD.PA page and Investing.com coverage.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.